# Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

> **NCT01307631** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Recurrent Uterine Corpus Carcinoma

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01307631
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2015-09-18
- **Final completion:** 2015-09-18
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01307631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01307631, "Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01307631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*